EUCTR2015-003286-28-GB进行中（未招募）1 期
A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination with Brentuximab Vedotin in Subjects with Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression - CheckMate 436: CHECKpoint pathway and nivolumab clinical Trail Evaluation
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Relapsed/refractory diffuse large B cell lymphoma (DLBCL), relapsed/refractory peripheral T cell lymphoma (PTCL) (all subtypes excluding anaplastic large cell lymphoma), relapsed/refractory Cutaneous T cell lymphoma (CTCL) mycosis fungoides/sezary syndrome (MF/SS), relapsed/refractory primary mediastinal B lymphoma (PMBL), and relapsed/refractory mediastinal gray zone lymphoma (MGZL)
- •Expression of CD30
- •Subjects must be 18 years or older (= 15 years for PMBL)
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 5
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 85
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 80
排除标准
- •Known central nervous system (CNS)
- •lymphomas; Active
- •cerebral/meningeal disease related
- •to the underlying malignancy
- •Active, known, or suspected autoimmune disease
研究者
相似试验
进行中（未招募）
1 期
A Safety and Efficacy Study of Nivolumab in Combination with Brentuximab Vedotin to Treat Non-Hodgkin LymphomasEUCTR2015-003286-28-ESBristol-Myers Squibb International Corporation144
进行中（未招募）
不适用
A Safety and Efficacy Study of Nivolumab in Combination with Brentuximab Vedotin to Treat Non-Hodgkin LymphomasEUCTR2015-003286-28-FRBristol-Myers Squibb International Corporation120
进行中（未招募）
1 期
A Safety and Efficacy Study of Nivolumab in Combination with Brentuximab Vedotin to Treat Non-Hodgkin LymphomasRelapsed Refractory Non Hodgkin Lymphomas with CD30 ExpressionMedDRA version: 20.0Level: HLTClassification code 10029606Term: Non-Hodgkin's lymphomas transformed recurrentSystem Organ Class: 100000004851EUCTR2015-003286-28-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO170
进行中（未招募）
不适用
A Phase IIA Study to Evaluate the Safety and Preliminary Efficacy of Resten-MP when used in Conjunction with a Bare Metal Stent in de novo Native Coronary Artery Lesions - APPRAISAEUCTR2005-000713-35-DEAVI BioPharma Inc.50
进行中（未招募）
1 期
The purpose of this study is to determine whether an investigational combination immuno-therapy of nivolumab and daratumumab is safe and effective in thetreatment of advanced or metastatic solid tumors.EUCTR2017-000367-33-FRBristol-Myers Squibb International Corporation105